In a patient with ADHD and insomnia who has failed a trial of a short‑acting hypnotic, what are the indications, dosing, efficacy, and safety considerations for using the sedating antidepressants mirtazapine or low‑dose tricyclic antidepressants (e.g., amitriptyline, doxepin)?

Sedating Antidepressants for ADHD-Related Insomnia After Hypnotic Failure

After failing a short-acting hypnotic, sedating antidepressants like mirtazapine or low-dose tricyclic antidepressants (TCAs) are appropriate third-line options for insomnia in ADHD patients, though evidence for their efficacy is relatively weak and they are not FDA-approved for this indication. 1

Clinical Context and Positioning

The American Academy of Sleep Medicine guidelines explicitly position sedating antidepressants as third-line therapy after benzodiazepine receptor agonists (BzRAs) have been tried 1. The recommended sequence is:

1. First: Short-intermediate acting BzRAs or ramelteon
2. Second: Alternate BzRA or ramelteon if initial agent unsuccessful
3. Third: Sedating antidepressants (trazodone, amitriptyline, doxepin, mirtazapine)
4. Fourth: Combined BzRA + sedating antidepressant

Important caveat: The guidelines note these medications are "especially when used in conjunction with treating comorbid depression/anxiety" 1. For ADHD patients without significant mood symptoms, this represents off-label use with limited evidence.

Specific Agent Recommendations

Mirtazapine

Dosing:

• Start: 15 mg at bedtime 2
• Can increase to 30-45 mg if inadequate response after 1-2 weeks 2
• Ultra-low doses (3.75-7.5 mg) show emerging evidence for insomnia-specific treatment 3, 4

Efficacy:

• Moderate evidence for sleep improvement in depression-related insomnia 5
• 62.4% insomnia remission rate at 6 weeks in depressed patients 5
• Critical limitation: No specific evidence for primary insomnia or ADHD-related insomnia
• The 2008 guidelines state "evidence for their efficacy when used alone is relatively weak" 1

Safety Considerations:

• Most common adverse effects (>10%): Increased appetite, drowsiness, weight gain, dry mouth, headache, constipation 2, 5
• Weight gain of ≥7% body weight in 7.5% of patients 2
• Next-morning sedation risk—caution with driving/operating machinery 2
• QTc prolongation possible, especially with overdose or other risk factors 2
• Low white blood cell count risk—monitor for fever, sore throat, infections 2
• Contraindicated with MAOIs (14-day washout required) 2

Low-Dose Tricyclic Antidepressants

Specific Agents:

Doxepin (preferred TCA for insomnia):

• Dosing: 3-6 mg at bedtime for sleep maintenance insomnia 6
• Only TCA with positive recommendation from 2017 AASM guidelines (weak recommendation) 6
• Lower anticholinergic burden than amitriptyline 1
• Moderate quality evidence shows improvement in sleep efficiency (6.29 percentage points increase) and total sleep time (22.88 minutes increase) 7

Amitriptyline:

• Dosing: Start 10-25 mg at bedtime 1, 4
• No RCT evidence exists despite widespread clinical use 7
• Higher anticholinergic activity than doxepin—greater risk of dry mouth, constipation, urinary retention, confusion (especially in elderly) 1
• May be superior for core depression symptoms but this doesn't apply to primary insomnia 8

Critical Safety Issues for TCAs:

• Anticholinergic effects: Dry mouth, constipation, urinary retention, confusion, blurred vision
• Cardiac effects: QTc prolongation, orthostatic hypotension 1
• Caution required in: respiratory compromise (asthma, COPD, sleep apnea), cardiac disease, elderly patients 1
• Not recommended in pregnancy/nursing 1
• Dose reduction needed in elderly and hepatically impaired patients 1

Evidence Quality Assessment

The evidence base is problematic:

1. No FDA approval for insomnia for any of these agents 1
2. Weak efficacy evidence: The 2008 AASM guidelines explicitly state "evidence for their efficacy when used alone is relatively weak" 1
3. Trazodone negative recommendation: The 2017 guidelines suggest NOT using trazodone for insomnia (50 mg dose studied) 6
4. No head-to-head comparisons with BzRAs or between different antidepressants 1
5. Short-term studies only: Most trials are 6-12 weeks; long-term efficacy unknown 7
6. No specific ADHD population data: All evidence is from primary insomnia or depression-related insomnia

Practical Clinical Algorithm

When to consider sedating antidepressants in ADHD + insomnia:

1. After documented failure of at least one BzRA (e.g., zolpidem, eszopiclone) 1
2. Presence of comorbid depression/anxiety makes them more appropriate 1
3. Concern about BzRA dependence in patient with substance use history
4. Sleep maintenance insomnia (not just sleep onset)—better target for these agents

Agent selection:

• First choice: Doxepin 3-6 mg (only TCA with positive guideline recommendation, lower anticholinergic burden) 6
• Second choice: Mirtazapine 7.5-15 mg (if appetite/weight gain acceptable, avoid if metabolic concerns) 1, 2
• Avoid: Amitriptyline (no evidence despite common use), Trazodone (negative recommendation) 6, 7

Monitoring Requirements

Initial phase (weeks 1-6):

• Assess effectiveness every 2-4 weeks 1
• Monitor for next-morning sedation/impairment
• Track weight (especially with mirtazapine)
• Screen for anticholinergic effects (TCAs)
• Assess for mood changes/activation

Ongoing:

• Regular follow-up every 6 months minimum 1
• Attempt dose reduction or discontinuation when conditions allow 1
• Taper gradually rather than abrupt discontinuation to avoid withdrawal 2

Critical Pitfalls to Avoid

1. Using as first-line therapy: These are third-line agents after BzRA failure 1
2. Assuming antidepressant doses work for insomnia: Low doses (often sub-antidepressant) are used 1
3. Ignoring anticholinergic burden: Particularly problematic in elderly, those with cognitive issues, or urinary/GI problems
4. Combining with other sedatives without caution: Additive CNS depression with benzodiazepines, alcohol 2
5. Not screening for bipolar disorder: Can precipitate mania 2
6. Overlooking cardiac risk factors: QTc prolongation risk with both mirtazapine and TCAs 2
7. Expecting robust evidence: Acknowledge to patients this is off-label use with limited data 1

Drug Interactions Relevant to ADHD

Mirtazapine:

• CYP3A4 interactions: Dose adjustment needed with strong inducers (carbamazepine) or inhibitors (ketoconazole) 2
• Avoid with stimulants + MAOIs: Serotonin syndrome risk 2

TCAs:

• Additive effects with other anticholinergics
• Cardiac monitoring if combined with other QTc-prolonging agents

Patient Education Points

• Timing: Take at bedtime, preferably on empty stomach for faster onset 1
• Driving: Avoid driving until certain of no next-morning impairment 2
• Alcohol: Avoid alcohol completely 2
• Weight: Expect possible weight gain with mirtazapine (discuss dietary strategies) 2
• Duration: Not intended as permanent solution; combine with sleep hygiene and CBT-I when possible 1
• Discontinuation: Must taper gradually, not stop abruptly 2